Mursla Bio is stepping up its expansion in the United States as it prepares to launch its liver cancer surveillance test, EvoLiver™.
Based at Cambridge Science Park with additional facilities in Boston, the company has been selected for the Association of British HealthTech Industries (ABHI) US Accelerator. The programme helps UK health technology companies build connections and navigate the US healthcare system.
EvoLiver™ is a blood test designed to improve the early detection of liver cancer in people at high risk of the disease. By using a new approach based on liver-cell biology, it aims to address key gaps in current monitoring methods.
Through the programme, Mursla Bio will connect with more than 300 senior healthcare leaders across hospitals, health systems and insurers, while also receiving guidance from organisations including Becton Dickinson and Dell Medical School at the University of Texas.
Pierre Arsène, Founder and CEO of Mursla Bio, said: “Bringing a new test into clinical use depends on reaching the right people across the healthcare system. This programme strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our EV diagnostics platform in the US.”